Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-19
    E.g., 2018-10-19

Archive Search

Pages

58 results
9:26 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Regulatory

FDA wants extra trial for Pharming's Ruconest as HAE Prophylactic

Shire plc (LSE:SHP; NASDAQ:SHPG) markets the human mAb against plasma kallikrein (KLKB1) as well as Cinryze
11:41 AM, Aug 31, 2018  |  BC Week In Review | Clinical News  |  Regulatory

FDA approves Shire's Takhzyro, first mAb to prevent HAE

a portfolio of HAE drugs that meet different patient needs. Among them is prophylactic treatment Cinryze
1:02 PM, Mar 02, 2018  |  BC Week In Review | Clinical News  |  Regulatory

Priority review for Shire's HAE prophylactic

a portfolio of HAE drugs that meet different patient needs. Among them is prophylactic treatment Cinryze
four days. Lanadelumab, which is dosed every two weeks, could provide a dosing benefit over Cinryze
12:16 PM, Sep 15, 2017  |  BC Week In Review | Clinical News  |  Clinical Results

Shire's subcutaneous HAE candidate meets in Phase III

SHP616 consecutively for 28 weeks. SHP616 is a lower-dose volume, subcutaneous liquid formulation of IV Cinryze
an IV therapy, or who have had complications of indwelling central catheters. Shire markets IV Cinryze
4:50 PM, Dec 19, 2016  |  BC Week In Review | Clinical News  |  Regulatory

Cinryze regulatory update

EMA’s CHMP recommended expanding the label of Cinryze from Shire for treatment and pre-procedure prevention of …
for routine prevention of attacks to include children ages 6-11 with severe and recurrent HAE. Cinryze
angioedema attacks in adults and adolescents with HAE. Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland  Product: Cinryze
12:00 AM, Oct 26, 2015  |  BC Week In Review | Clinical News  |  Regulatory

Cinryze regulatory update

FDA granted Fast Track designation to Cinryze from Shire to treat antibody-mediated rejection in patients who …
of the month, the company will start a double-blind, placebo-controlled, international Phase III trial of Cinryze
attacks in patients with hereditary angioedema (HAE). Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland   Product: Cinryze
12:00 AM, Dec 09, 2013  |  BC Week In Review | Company News  |  Deals

Shire, ViroPharma deal

non-binding proposal of $50 per share contingent upon a visit to ViroPharma's partner's facilities where Cinryze
12:00 AM, Nov 18, 2013  |  BC Week In Review | Company News  |  Deals

Shire, ViroPharma deal

on rumors of a possible auction after receiving an unsolicited bid. Shire will gain ViroPharma's Cinryze
12:00 AM, Aug 05, 2013  |  BC Week In Review | Clinical News  |  Clinical Status

Subcutaneous Cinryze: Phase IIb discontinued

ViroPharma discontinued a double-blind, crossover, international Phase IIb trial evaluating subcutaneous Cinryze in combination with Halozyme's …
trial, which completed enrollment of 41 adolescent and adult patients, was evaluating 1,000 units subcutaneous Cinryze
plus 24,000 units rHuPH20 twice weekly and 2,000 units Cinryze plus 48,000 units rHuPH20 twice weekly …
12:00 AM, Apr 01, 2013  |  BC Week In Review | Clinical News  |  Regulatory

Cinryze regulatory update

The All Wales Medicines Strategy Group (AWMSG) recommended the use of Cinryze from ViroPharma on the …
and pre-procedural prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE). Specifically, Cinryze
for routine prophylaxis of acute attacks of HAE. ViroPharma Inc. (NASDAQ:VPHM), Exton, Pa.   Product: Cinryze

Pages